Navigation Links
Dismissal of Lawsuit by Former Officer Affirmed by Appellate Court
Date:9/23/2010

ORLANDO, Fla., Sept. 23 /PRNewswire/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, is pleased to report that the Superior Court of Pennsylvania has affirmed the dismissal of the complaint filed by the Company's former CEO and President, John DePhillipo, and his wife (collectively, the "DePhillipos") against the Company, its subsidiary GeneWize Life Sciences, Inc., and several of the Company's officers, directors and advisors (collectively, the "GeneLink Parties").  The DePhillipos' appeal arose from the May 5, 2009 Order and Opinion of the Court of Common Pleas of Pennsylvania, Philadelphia County wherein that Court dismissed the DePhillipos' claims as unviable.  


About GeneLink BioSciences, Inc.:

GeneLink BioSciences is a genomics, biotechnology, and wellness company engaged in genetic profile development, product development, business development and support services for its subsidiaries and distribution partners.  GeneLink's patented and patent pending technologies include proprietary genetic assessments and products linked to personalized health, beauty and wellness applications. For additional information, please visit www.genelinkbio.com.


This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE GeneLink BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
2. Supreme Court Amicus Brief Filed Opposing Lawsuit Protection for Manufacturers of Defectively Designed Vaccines
3. First DePuy ASR Hip Replacement Lawsuit Filed in the US
4. UPDATE: Appeal of Lawsuit by Former Chief Executive Officer- Reinstated; and Sanctions Order Vacated
5. Appeal of Lawsuit by Former Chief Executive Officer- Reinstated; and Sanctions Order Vacated
6. Appeal of Lawsuit by Former Officer Dismissed; Request for Sanctions Granted
7. Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
8. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
9. ASCP Joins ACLU Lawsuit Opposing Gene Patents
10. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
11. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017  ArmaGen, Inc., a privately ... to treat severe neurological disorders, today reported preliminary ... AGT-181, the company,s investigational therapy for the treatment ... mucopolysaccharidosis type I, or MPS I). The initial ... study, presented today at the 13 th ...
(Date:2/16/2017)... DENVER , Feb. 16, 2017 UCHealth ... hospital to utilize LungDirect for pulmonary nodule patient management. ... a nodule, or a spot on the lung, UCHealth ... spent on manual data entry. Stephanie ... been tracking my nodule patients with an Excel spreadsheet, ...
(Date:2/16/2017)... 16, 2017  Rhythm, a biopharmaceutical company ... that result in life-threatening metabolic disorders, today ... mezzanine round of financing with existing investors ... New Enterprise Associates, Pfizer Venture Investments, Third ... investment fund. Rhythm will use the proceeds ...
(Date:2/15/2017)... 15. Februar 2017  Trianni, Inc. („TRIANNI") gab ... (Janssen) eine Lizenzvereinbarung über die Verwendung der The ... Plattform für die Entdeckung monoklonaler Antikörper. ... chimäres Gensegmentdesign aus, das Janssen den Zugang ... bietet und das für die schelle Isolierung vollständig ...
Breaking Biology Technology:
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile ... smartphone prices have dropped dramatically. The quarterly average price ... 2013 to $276 in Q4 2016.  There are now ... price of $116, up from just 28 a year ... According to Maxine Most , Acuity Market ...
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic ... to mergers and acquisitions (M&A), and Kalorama Information expects ... such acquisitions have been shifting. Generally, uncertainty in reimbursement ... and the U.S. has changed the acquisitions landscape. Instead ... resulted in companies buying partners outside of their home ...
Breaking Biology News(10 mins):